Pioneering Early Cancer Detection
Through Smart Genomics
Molecular intelligence that helps clinicians identify risk earlier, guide therapy with confidence and improve patient outcomes through high-quality genomic testing.
From Complex Data to Clear Decisions
Clinical Insight, Faster
Analysis workflows, interpretation support and software modules that help laboratory teams turn sequencing data into confident, report-ready answers.
Connected Labs Across India
Access Without Distance
Genient brings validated tests, instruments, training and interpretation closer to hospitals, districts, reference labs and national programmes.
Your Genomics Companion
Friendly Science, Serious Precision
A warm guide for a serious mission: making advanced molecular diagnostics understandable, deployable and useful for Indian healthcare teams.
Equitable access
What equitable access means to us
Genomics should not stay locked inside a few central labs. Genient helps healthcare teams choose the right test, set up the right workflow and bring advanced molecular answers closer to the patient.
Access beyond metros
Workflows designed for reference centres, district laboratories and public health programmes.
Validated technologies
NGS, RT-PCR, POC and lab automation platforms selected for reliability and scale.
"Equitable genomics is ultimately not about how much we can sequence. It is about how many lives can benefit from what we learn."
For me, equitable access to genomics is not simply about bringing new technology to India. It is about ensuring that its clinical value reaches every patient who can benefit from it.
At Genient Technologies, this conviction shapes what we are building: platform-agnostic, India-relevant molecular and NGS solutions across infectious diseases, antimicrobial resistance, oncology and other areas of precision diagnostics.
Our ambition is to help move genomics beyond a few specialised centres and closer to routine clinical care, laboratories and public-health programmes.
Our pledge
To make precision genomics more accessible, reliable and
clinically actionable.
India's demographic dividend
A young nation's dividend only pays if its people stay healthy.
India has the largest working-age population in the world. Diagnosing cancer earlier, stopping resistant infections and understanding the Indian genome protect that workforce for decades. Equitable access to genomics is how the dividend is secured.
Precision medicine in India
From uniform treatment to individualized, evidence-guided care
The global shift toward value-based healthcare is driving wider adoption of precision medicine, with genomics at its core. Genomic insights are moving clinical practice beyond uniform treatment models toward individualized, evidence-guided care.
This transition strengthens the economic and clinical rationale for embedding precision medicine and genomics into preventive and predictive health frameworks.
-
01
Digitize
Capture genomic and clinical records in structured digital form at the point of testing.
-
02
Harmonize
Align formats, terminologies and quality standards so data from different labs can be combined.
-
03
Integrate
Link genomic results with clinical outcomes into clinico-genomic real-world datasets.
-
04
Inform care
Analytics, clinical decision support and structured reporting that clinicians can act on.
What we do
View full portfolio
Six clinical domains, from first test to full genome.
Equitable access in practice: platform-agnostic, India-relevant solutions that connect robust assays with bioinformatics and clinical interpretation.
Early cancer detection
Early cancer detection
Liquid biopsy and precision oncology that find cancer when treatment still works best. Multi-cancer early detection, methylation liquid biopsy, FastGen oncology and in-house sequencing.
Precision oncology portfolio
Infectious disease
Infectious disease and drug resistance
Syndromic diagnosis in hours, then the resistance profile that decides therapy. Respiratory, sepsis, STI, tropical fever and DeepChek® resistance genotyping.
Infectious disease portfolio
Pathogen genomics
Pathogen genomics and epidemiology
Sequencing that tells you which strain, how it spreads and whether it is resistant. Viral WGS, bacterial WGS, disease epidemiology and AbSeq portable sequencers.
Portable sequencing
Population genomics
Population genomics
Large-scale programmes that map the Indian genome, still under-represented in global reference data. WGS/WES, population-scale programmes, pharmacogenomics and NIPT.
Sequencing and genomics portfolio
Reproductive genetics
Reproductive and population genetics
NIFTY, carrier screening, embryo screening, rare disease and population-scale genomics for every new beginning.
Explore genetics
Bioinformatics
Bioinformatics and interpretation
Data analysis, reporting, software modules and clinical interpretation support for NGS programmes that turn raw reads into confident, report-ready answers.
Support analysis
Infectious disease
From syndrome to sequence to surveillance
Fast molecular testing and sequencing-led interpretation help teams move from a patient symptom to a public health signal.
Detect
Multiplex RT-PCR panels identify pathogens quickly across respiratory, sepsis, STI, UTI and GI syndromes.
Characterize
Genotyping and WGS reveal variants, resistance markers and clinically relevant mutations.
Interpret
Bioinformatics, software and expert reporting turn raw reads into actionable clinical and programme insight.
AbSeq portable sequencers
Explore AbSeq
Sequencing on your own bench, not in someone else's queue.
A compact sequencing workflow that brings NGS into microbiology and pathology labs, so teams no longer wait on a send-out for every answer.
For microbiologists
Characterise isolates and outbreaks where the samples are.
- Viral and bacterial whole-genome sequencing
- AMR gene and resistance mutation detection
- Pan-infection identification when culture and PCR fall short
- Strain typing for infection control and outbreak response
For oncology pathologists
Targeted tumour sequencing for pathology department.
- Targeted tumour panels run in-house
- Shorter turnaround than external send-outs
- Sample custody stays within your institution
- Bioinformatics and reporting support from Genient scientists
Focus zone
Partners and products built for adoption
Three technologies that carry equitable access furthest today: resistance genotyping, syndromic PCR and population-scale sequencing.
ABL Diagnostics, France
DeepChek® resistance genotyping
NGS drug-resistance testing for HIV and TB, with AI-assisted interpretation. DeepChek® pairs next-generation sequencing assays with interpretation software that turns resistance mutations into a clear report, helping clinicians choose regimens that work for patients in India's HIV and TB programmes.
Targets HIV and TB drug resistance
Who it is for Reference and programme laboratories
Technology NGS with AI-assisted interpretation
Partner ABL Diagnostics, France
Bioeksen, Turkey
Bio-Speedy® syndromic multiplex RT-PCR
Several pathogens, one sample, one run. Bio-Speedy® multiplex real-time RT-PCR kits bring syndromic testing for respiratory and other infections to hospital and district laboratories, so a patient gets a pathogen-level answer without a referral to a metro reference centre.
Technology Multiplex real-time RT-PCR
Applications Syndromic and respiratory testing
Who it is for Hospital, district and reference labs
Partner Bioeksen, Turkey
BGI Genomics, China
Population genomics and NGS instruments
Sequencing capacity for genome-scale programmes, from benchtop to high-throughput. BGI Genomics sequencing instruments and workflows for whole-genome, whole-exome, NIPT and population genomics, so Indian institutes can generate genomic data at national scale, at a cost per genome that makes equitable access realistic.
Platforms Benchtop to high-throughput NGS
Applications WGS, WES, NIPT, population genomics
Who it is for Genome centres, apex institutes,
programmes
Partner BGI Genomics, China
Our customers
Trusted by India's leading institutions
Apex government institutes, hospital networks and national reference laboratories run technologies and services delivered by Genient.
Brands and partners
View Partners
A connected ecosystem for advanced diagnostics
Specialized diagnostic, sequencing and interpretation platforms brought together with local scientific, regulatory and implementation support.
ABL Diagnostics
France · Luxembourg — Exclusive — India DeepChek® NGS genotyping and drug-resistance assays; UltraGene qPCR line.
BGI Genomics
China — Channel partner DNBSEQ sequencers (G50 / G99 / G400), NIFTY® prenatal screening, library prep and bioinformatics
Bioeksen
Türkiye — Exclusive — India Molecular diagnostics manufacturer of the Bio-Speedy® syndromic panel range.
Bio-Speedy
Türkiye — Exclusive — India Multiplex syndromic qPCR panels — sepsis, respiratory, GI, STI, HPV.
Invitek Diagnostics
Germany — Exclusive — India Spin-column and magnetic-bead extraction; InviScreen® / InviLisa® food-safety portfolio AIT Biotech — 🇸🇬 Singapore — Exclusive — India.
AIT Biotech
Singapore — Exclusive — India abSEQ™ genetic sequencer and abNEX™ pathogen genomics ID / AMR NGS panels
SML Genetree
South Korea — Partnership Sepsis / bloodstream-infection multiplex PCR panel co-development.
BioVendor R&D
Czech Republic — Partnership Immunoassay and research reagent portfolio
Siemens Healthineers
Germany — Heritage Promoters led the FTD Asia amalgamation into Siemens Healthineers
Fast-Track Diagnostics
Luxembourg — Heritage Multiplex PCR pioneer; promoters’ former board roles (acquired by Siemens Healthineers)
Haplox
NGS based Precision Oncology, CGP, TMB and MRD with tertiary analysis and reporting.
Network
A global network, one window for India
Genient brings global diagnostics, sequencing and medtech partners into Indian clinical workflows with local support.
Genient in the news
Coverage and announcements
Milestones across precision diagnostics, public health programmes and global partnerships.
MICROCON 2026, Nagpur: Read our genomics preview
Public health
Genient awarded HIV drug-resistance and genotyping project by MoHFW
National access
Read story
Partnership
ABL Diagnostics and Genient sign exclusive agreement for DeepChek® NGS assays
Clinical innovation
Read story
Implementation
Turnkey biotechnology research lab delivered for University of Delhi
Research infrastructure
Read story
Start a conversation
Bring advanced genomics closer to your patients.
Tell us what your laboratory, hospital or programme needs. Genient can help you shape the right path from test selection to implementation.
Contact us
Ask Genient